Market Cap
US$6.1b
Last Updated
2020/10/20 00:01 UTC
Data Sources
Company Financials +
Executive Summary
Natera, Inc. provides preconception and prenatal genetic testing services. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with concerning outlook.
Similar Companies
Share Price & News
How has Natera's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NTRA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-0.6%
NTRA
-3.4%
US Biotechs
-2.4%
US Market
1 Year Return
93.2%
NTRA
35.9%
US Biotechs
18.2%
US Market
Return vs Industry: NTRA exceeded the US Biotechs industry which returned 39.3% over the past year.
Return vs Market: NTRA exceeded the US Market which returned 19.5% over the past year.
Shareholder returns
| NTRA | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.6% | -3.4% | -2.4% |
| 30 Day | 19.9% | 0.7% | 4.2% |
| 90 Day | 46.6% | -4.7% | 6.3% |
| 1 Year | 93.2%93.2% | 38.3%35.9% | 20.9%18.2% |
| 3 Year | 479.0%479.0% | 18.5%12.5% | 41.2%31.8% |
| 5 Year | 740.7%740.7% | 17.2%8.9% | 84.8%63.9% |
Price Volatility Vs. Market
How volatile is Natera's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Read This Before Buying Natera, Inc. (NASDAQ:NTRA) Shares1 month ago | Simply Wall St
Did The Underlying Business Drive Natera's (NASDAQ:NTRA) Lovely 375% Share Price Gain?2 months ago | Simply Wall St
Is Natera (NASDAQ:NTRA) Using Debt Sensibly?Valuation
Is Natera undervalued compared to its fair value and its price relative to the market?
19.01x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NTRA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NTRA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NTRA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: NTRA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NTRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NTRA is overvalued based on its PB Ratio (19x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Natera forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
18.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NTRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NTRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NTRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NTRA's revenue (13.7% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: NTRA's revenue (13.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NTRA is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Natera performed over the past 5 years?
-16.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NTRA is currently unprofitable.
Growing Profit Margin: NTRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NTRA is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare NTRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: NTRA has a negative Return on Equity (-50.39%), as it is currently unprofitable.
Next Steps
Financial Health
How is Natera's financial position?
Financial Position Analysis
Short Term Liabilities: NTRA's short term assets ($663.5M) exceed its short term liabilities ($175.6M).
Long Term Liabilities: NTRA's short term assets ($663.5M) exceed its long term liabilities ($243.4M).
Debt to Equity History and Analysis
Debt Level: NTRA's debt to equity ratio (81.4%) is considered high.
Reducing Debt: NTRA's debt to equity ratio has increased from 59.6% to 81.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NTRA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NTRA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.3% each year
Next Steps
Dividend
What is Natera current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NTRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NTRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NTRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NTRA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NTRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Steve Chapman (41 yo)
1.75yrs
Tenure
US$6,200,911
Compensation
Mr. Steve Chapman has been Chief Executive Officer at Natera, Inc. since January 02, 2019 and serves as President and Director at Natera, Inc. since January 02, 2019. Mr. Chapman served as Chief Operating ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD6.20M) is about average for companies of similar size in the US market ($USD7.31M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 5.42yrs | US$2.51m | 1.76% $ 107.1m | |
| CEO, President & Director | 1.75yrs | US$6.20m | 0.044% $ 2.7m | |
| Co-Founder | 13.75yrs | US$752.68k | 0.33% $ 20.1m | |
| Chief Financial Officer | 3.67yrs | US$3.54m | 0.068% $ 4.1m | |
| Chief Operating Officer | 1.75yrs | US$4.12m | 0.063% $ 3.8m | |
| Chief Scientific Officer | 0.67yr | no data | no data | |
| Secretary & General Counsel | no data | no data | no data | |
| Vice President of Sales | 4.58yrs | no data | no data | |
| Vice President of Marketing & Medical Education | 4.58yrs | no data | no data | |
| VP of Corporate Marketing | no data | no data | no data | |
| Senior Vice President of R&D - Data Science & Engineering | 2.25yrs | no data | no data | |
| Chief Scientific Officer for Oncology | 4.92yrs | no data | no data |
3.0yrs
Average Tenure
47yo
Average Age
Experienced Management: NTRA's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 5.42yrs | US$2.51m | 1.76% $ 107.1m | |
| CEO, President & Director | 1.75yrs | US$6.20m | 0.044% $ 2.7m | |
| Co-Founder | 13.75yrs | US$752.68k | 0.33% $ 20.1m | |
| Independent Director | 5.92yrs | US$481.79k | 0.035% $ 2.1m | |
| Independent Director | 3.67yrs | US$479.24k | 0.058% $ 3.5m | |
| Independent Director | 9.75yrs | US$494.36k | 0.0087% $ 528.1k | |
| Lead Independent Director | no data | US$504.18k | 1.31% $ 80.0m | |
| Independent Director | 3.58yrs | US$508.16k | 0% $ 0 | |
| Independent Director | 2.25yrs | US$322.90k | 0% $ 0 | |
| Independent Director | 1.17yrs | US$608.72k | no data |
3.7yrs
Average Tenure
52yo
Average Age
Experienced Board: NTRA's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NTRA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.8%.
Top Shareholders
Company Information
Natera, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Natera, Inc.
- Ticker: NTRA
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.098b
- Shares outstanding: 84.05m
- Website: https://www.natera.com
Number of Employees
Location
- Natera, Inc.
- 201 Industrial Road
- Suite 410
- San Carlos
- California
- 94070
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NTRA | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jul 2015 |
| 45E | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2015 |
Biography
Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/20 00:01 |
| End of Day Share Price | 2020/10/19 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.